Nasrallah IM, et al. - Herein, experts ascertained if ¹⁸F-flortaucipir (also known as ¹⁸F-AV-1451) PET, targeting tau aggregates, identified the nonamnestic Alzheimer's disease (AD) variants varying from amnestic AD in distributions of tau aggregates and neurodegeneration. Additionally, they contrasted the outcomes with MRI measures of gray matter (GM) atrophy. It was demonstrated that ¹⁸F-flortaucipir binding corresponded to the expected neurodegeneration patterns in nonamnestic AD. It displayed the potential for earlier recognition of pathology when compared to MRI atrophy measures.